Loading...
XNASTARA
Market cap202mUSD
Jan 08, Last price  
5.91USD
1D
-1.17%
1Q
264.81%
Jan 2017
-92.22%
IPO
-98.52%
Name

Protara Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:TARA chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
34.65%
Rev. gr., 5y
%
Revenues
0k
2,948,000000000000
Net income
-40m
L-37.64%
-3,342,000-21,377,000-28,526,000-29,964,000-25,437,000-14,730,000-33,512,000-47,135,000-64,815,000-40,420,000
CFO
-38m
L+41.95%
-9,990,000-17,566,000-23,687,000-22,352,000-23,233,000-15,646,000-23,407,000-34,502,000-26,457,000-37,557,000
Earnings
Mar 11, 2025

Profile

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
URL
https://protaratx.com/
IPO date
Oct 22, 2014
Employees
25
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
43,954
37,792
Unusual Expense (Income)
NOPBT
(43,954)
(37,792)
NOPBT Margin
Operating Taxes
(1,137)
Tax Rate
NOPAT
(43,954)
(36,655)
Net income
(40,420)
-37.64%
(64,815)
37.51%
Dividends
Dividend yield
Proceeds from repurchase of equity
(91)
(90)
BB yield
0.43%
0.30%
Debt
Debt current
1,966
917
Long-term debt
9,951
11,851
Deferred revenue
Other long-term liabilities
Net debt
(53,663)
(89,488)
Cash flow
Cash from operating activities
(37,557)
(26,457)
CAPEX
(45)
(120)
Cash from investing activities
53,107
14,950
Cash from financing activities
(91)
(90)
FCF
(42,645)
(35,634)
Balance
Cash
65,580
84,370
Long term investments
17,886
Excess cash
65,580
102,256
Stockholders' equity
(200,404)
(160,641)
Invested Capital
275,175
269,108
ROIC
ROCE
EV
Common stock shares outstanding
11,331
11,260
Price
1.88
-30.03%
2.68
-60.30%
Market cap
21,247
-29.59%
30,176
-60.20%
EV
(32,416)
(59,312)
EBITDA
(43,613)
(37,544)
EV/EBITDA
0.74
1.58
Interest
1,137
Interest/NOPBT